-
TR1 from Lanstead – Major interest in shares
TR-1: Standard form for notification of major holdings from Lanstead To download form click here
-
Proactive
ImmuPharma CEO on oversubscribed fundraising and strong 2025 outlook January 2025 Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor about the recent oversubscribed fundraising and strong outlook for 2025 – February 2025
-
Lanstead Subscription & Oversubscribed Placing to ‘c.£2.91 million | Sharing Agreement | Related Party Transactions
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce an equity fundraise of c.£2.91 million, utilising existing authorities to allot shares (the “Fundraise”). The Fundraise comprises a) an oversubscribed placing to raise gross proceeds of £1.034 million through the issue of 27,586,667 new ordinary shares of 1 pence…
-
Response to Share Price Movement
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes the recent movements in its share price. As announced on 9 January 2025, the Company has made innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company’s R&D subsidiary ImmuPharma…
-
Sunday Roast
Sunday Roast featuring Tim McCarthy, CEO of ImmuPharma January 2025 Tim McCarthy, CEO of ImmuPharma, joins Sunday Roast podcast to discuss how the company is revolutionizing healthcare with peptide-based therapies – Jan 2025
-
Proactive
Proactive – ImmuPharma “looking forward” to upcoming FDA meetings January 2025 ImmuPharma’s CEO Tim McCarthy shares latest developments with P140 platform and exciting road ahead with business development over 2025 – January 2025
-
ImmuPharma Announces Breakthrough Findings into Autoimmune Diseases
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company’s R&D subsidiary ImmuPharma Biotech, has yielded compelling data that provides novel insights into autoimmune disease mechanisms. Importantly for our autoimmune…
-
Immupharma at JP MORGAN CONFERENCE and BIOTECH SHOWCASE 11-16 January 2025, San Francisco
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be attending both the JP Morgan Conference and the Biotech Showcase from 11-16 January 2025, in San Francisco. The JP Morgan conference and Biotech…
-
Change of Auditor
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces the appointment of Crowe LLP (“Crowe”) as the Company’s new auditor, succeeding CLA Evelyn Partners Limited, with immediate effect. Crowe will conduct the audit of the Company’s financial statements for the financial year ending 31 December 2024 and a proposal to reappoint them…
-
Appointment of Company Secretary
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm the appointment of Ashley Clarke ACA, as Company Secretary to the Company. The appointment is with immediate effect. Ashley has been closely involved with the Company’s accounts for several years via outsourced accountants, providing her with deep familiarity with ImmuPharma’s operations.…
